Loading…
Pyxis Oncology, Inc. is projected to rise to $3.20 by 2027, a +20% move from its current price of $2.67. PYXS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.49 | $2.67 | $2.87 | +0.08% |
| Jul 14 | $2.42 | $2.67 | $2.96 | +0.16% |
| Jul 15 | $2.37 | $2.68 | $3.03 | +0.23% |
| Jul 16 | $2.32 | $2.68 | $3.09 | +0.31% |
| Jul 17 | $2.29 | $2.68 | $3.14 | +0.39% |
| Jul 18 | $2.25 | $2.68 | $3.19 | +0.47% |
| Jul 19 | $2.22 | $2.68 | $3.24 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.22 | $2.68 | $3.24 | +0.54% |
| Week 2 | $2.07 | $2.70 | $3.52 | +1.09% |
| Week 3 | $1.96 | $2.71 | $3.76 | +1.64% |
| Week 4 | $1.87 | $2.73 | $3.97 | +2.20% |
| Week 5 | $1.80 | $2.74 | $4.18 | +2.75% |
| Week 6 | $1.74 | $2.76 | $4.37 | +3.31% |
| Week 7 | $1.69 | $2.77 | $4.56 | +3.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pyxis Oncology, Inc. is a healthcare company focused on developing therapeutics to treat solid tumors. It is a clinical-stage company with a portfolio of investigational therapies, including PYX-201, an antibody-drug conjugate (ADC) in Phase 1 trials; PYX-102, an immunotherapeutic targeting KLRG1.
PYX-106 is a Siglec-15-targeting IO antibody in Phase 1, and PYX-107 is a CD40 agonist in Phase 2 for several cancer indications, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers, and pancreatic ductal adenocarcinoma.
The company has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106.
Pyxis Oncology was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Current price: $2.69. Market cap: $170.43M. Rank: 3924.
Pyxis Oncology trades at $2.69 per share and has a market capitalization of $170.43M, placing it at rank 3924 by market cap.
Forecasts show a path of rising value, with the average price projected to be $2.69 in 2026 and climbing to $70.49 by 2050. The max forecasts suggest substantial upside, with $4.22 in 2026 and $162.13 in 2050.
By 2030, the avg is $7.55 (ROI 180.6%), by 2040 it's $19.88 (ROI 638.9%), and by 2050 it's $70.49 (ROI 2520.5%). These imply significant upside if the forecasts materialize, but these are estimates, not guarantees.
A major floor 59.9% below — a decisive break under it would weaken the trend.
The nearest floor, 37.5% below — buyers have tended to step in here.
The nearest ceiling, 15.0% above — a clean break opens room to run.
A major ceiling 44.9% above — clearing it would confirm fresh momentum.
Key PYXS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PYXS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.71 | Sell | $2.70 | Sell |
| MA 10 | $2.77 | Sell | $2.63 | Buy |
| MA 20 | $2.36 | Buy | $2.45 | Buy |
| MA 50 | $2.12 | Buy | $2.17 | Buy |
| MA 100 | $1.83 | Buy | $2.05 | Buy |
| MA 200 | $2.34 | Buy | $2.05 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.78 | Neutral |
| Stoch RSI (14) | 2.41 | Buy |
| CCI (20) | 51.16 | Neutral |
| Williams %R (14) | -41.24 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 27.14 | Buy |
| Bollinger %B (20,2) | 0.67 | Neutral |
| Stochastic %K (14) | 58.76 | Neutral |
| TRIX (15) | 1.48 | Buy |
| Awesome (5,34) | 0.60 | Buy |
| Ultimate (7,14,28) | 49.28 | Neutral |
| Momentum (10) | 0.44 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 2.70 | Sell |
| ADX (14) | 25.01 | Buy |
| ATR (14) | 0.16 | Info |
Sentiment: BULLISH. RSI14: 60. SMA50: $2.08. SMA200: $2.34. Support: $1.63. Resistance: $3.07.
The 30-day range spans from a low of $1.64 to a high of $4.42, and annualized volatility sits at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.15 | $2.67 | $4.16 | 0% | Neutral | |
| $2.32 | $3.20 | $4.77 | +20% | Neutral | |
| $2.43 | $3.56 | $5.65 | +33% | Bullish | |
| $3.21 | $4.96 | $8.26 | +86% | Bullish | |
| $4.64 | $7.51 | $13.03 | +181% | Bullish | |
| $5.43 | $9.18 | $16.50 | +244% | Bullish | |
| $5.12 | $9.02 | $16.72 | +238% | Bullish | |
| $5.61 | $10.30 | $19.61 | +286% | Bullish | |
| $5.82 | $11.11 | $21.69 | +316% | Bullish | |
| $5.41 | $10.74 | $21.46 | +302% | Bullish | |
| $8.91 | $19.80 | $43.46 | +641% | Bullish | |
| $31.36 | $69.69 | $160.29 | +25.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.15 | $2.67 | $3.21 | +0.00% |
| August 2026 | $2.16 | $2.61 | $3.29 | -2.20% |
| September 2026 | $2.33 | $2.87 | $3.69 | +9.75% |
| October 2026 | $2.46 | $3.06 | $4.02 | +6.94% |
| November 2026 | $2.40 | $3.02 | $4.02 | -1.42% |
| December 2026 | $2.43 | $3.09 | $4.16 | +2.18% |
Click any year to see its month-by-month PYXS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PYXS could reach as high as $4.16, with a base case around $2.67 and support toward $1.15 — roughly 0% from $2.67. A consolidation phase looks the most probable path here.
Expect PYXS to range from $2.32 to $4.77 through 2027. The $3.20 average target implies a +20% move from current prices. That is up +20% on the projected 2026 average. Price action looks broadly range-bound.
The PYXS price prediction for 2028 points to an average of $3.56 (low $2.43, high $5.65) — a potential gain of +33% on today's $2.67. Buyers look set to stay in control over this stretch.
In 2029, PYXS is projected to trade between $3.21 and $8.26, averaging $4.96 — a potential gain of +86% from today's $2.67. That is up +39% on the projected 2028 average. Momentum favours further upside here.
Pyxis Oncology, Inc.'s 2030 outlook centres on $7.51, within a $4.64 to $13.03 range. That is up +52% on the projected 2029 average. That marks a +181% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, PYXS could reach as high as $16.50, with a base case around $9.18 and support toward $5.43 — roughly +244% from $2.67. Momentum favours further upside here.
Expect PYXS to range from $5.12 to $16.72 through 2032. The $9.02 average target implies a +238% move from current prices. That is -2% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The PYXS price prediction for 2033 points to an average of $10.30 (low $5.61, high $19.61) — a potential gain of +286% on today's $2.67. Momentum favours further upside here.
In 2034, PYXS is projected to trade between $5.82 and $21.69, averaging $11.11 — a potential gain of +316% from today's $2.67. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Pyxis Oncology, Inc.'s 2035 outlook centres on $10.74, within a $5.41 to $21.46 range. That is -3% versus the projected 2034 average. That marks a +302% change versus current levels. Momentum favours further upside here.
By 2040, PYXS could reach as high as $43.46, with a base case around $19.80 and support toward $8.91 — roughly +641% from $2.67. Buyers look set to stay in control over this stretch.
Expect PYXS to range from $31.36 to $160.29 through 2050. The $69.69 average target implies a +25.1x move from current prices. That is up +252% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PYXS today (≈ 374.531835 PYXS) could be worth
$26,101.91
+$25,101.91 (+2510%) by 2050 · US Dollar
Based on the average projected PYXS price of $69.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PYXSwould be worth at today's price.
$1,000 invested in PYXS on Jul 10, 2025 (≈ 840.336094 PYXS) would be worth
$2,243.7
+$1,243.7 (+124.4%) today · 2.24× · US Dollar
Based on a PYXS entry price of $1.19 vs. today's $2.67.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.63 | $1,015.21 | +1.5% |
| 1 month ago | $1.67 | $1,598.8 | +59.9% |
| 3 months ago | $1.7 | $1,570.59 | +57.1% |
| 6 months ago | $2.06 | $1,296.12 | +29.6% |
| 1 year ago | $1.19 | $2,243.7 | +124.4% |
| All time (4.8y) ago | $13.2 | $202.27 | -79.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PYXS forecast.
Our base-case forecast reaches $5.30 around 2030.
Implied market cap at $5.30: $335.78M
The year-by-year forecast shows a path of rising value across the horizon. In 2026 the min is $1.15, the avg $2.69, and the max $4.22 (ROI 0; sentiment NEUTRAL). By 2030 the avg is $7.55 with a 180.6% ROI and a bullish stance, and by 2040 the avg is $19.88 with a 638.9% ROI and a bullish stance.
By 2050 the avg is $70.49 with a 2520.5% ROI and a bullish stance.
Sentiment transitions from NEUTRAL in 2026-2027 to BULLISH from 2028 onward, with the strongest upside projected into the 2030s, 2040s, and 2050. Key catalysts cited in the background include multiple ADC and IO candidates in Phase 1 (and some in Phase 2), and licensing agreements with Pfizer and Biosion USA that could influence the trajectory if clinical results support expansion.
These projections are estimates and not guarantees. Realized returns depend on clinical outcomes, regulatory approvals, and market dynamics, among other factors.
Tap a question to reveal the answer.
Avg $7.55; min $4.66; max $13.10; ROI 180.6%; sentiment BULLISH.
Forecasts show bullish sentiment from 2028 onward, with Avg prices rising to $7.55 by 2030 and $70.49 by 2050; ROI figures indicate meaningful upside, but these are estimates, not guarantees.
Yes—the max forecast for 2050 is $162.13.
Current price $2.69; market cap $170.43M.
30-day range low $1.64, high $4.42; annualized volatility 100%.
Pyxis Oncology, Inc. Community Discussion
0Share your Pyxis Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.